STAT+: Pharmalittle: We’re reading about FDA naming Pazdur as top drug regulator, a cancer drug gold rush, and more

The appointment of Richard Pazdur as CDER director brings stability to the FDA amidst staff departures and industry concerns. This move is crucial for biotech/pharma professionals as it signals a consistent leadership focus on drug evaluation, potentially streamlining regulatory processes and decision-making for drug development.